IVF Market Size and Forecast 2025–2033

The global In Vitro Fertilization (IVF) market is entering a phase of sustained expansion as medical science, social acceptance, and demographic realities converge. According to Renub Research, the IVF market was valued at US$ 26.43 billion in 2024 and is projected to reach US$ 49.12 billion by 2033, growing at a CAGR of 7.13% during 2025–2033. This impressive trajectory reflects a worldwide rise in infertility, delayed parenthood, and growing reliance on advanced assisted reproductive technologies.

Download Free Sample Report

Once considered a niche medical procedure, IVF has now become a mainstream reproductive solution. Technological advancements, improved success rates, greater affordability, and broader social acceptance have transformed IVF into a widely adopted pathway to parenthood for couples, individuals, and diverse family structures across the globe.

Understanding the IVF Market

In-vitro fertilization is a cornerstone of assisted reproductive technology (ART). It involves the retrieval of mature eggs, fertilization in a laboratory environment, and the transfer of embryos into the uterus. IVF is frequently combined with complementary procedures such as intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), donor programs, and cryopreservation.

IVF is used to treat a range of fertility challenges including tubal blockages, endometriosis, ovulation disorders, low sperm count, unexplained infertility, and fertility preservation prior to cancer treatment. Increasingly, it also supports family planning for single parents by choice and LGBTQ+ couples, reinforcing its role not only as a medical solution but also as a social equalizer.

The market encompasses fertility drugs, laboratory equipment, cryopreservation systems, imaging technologies, genetic screening tools, and fertility clinic services. Rising demand across both developed and emerging economies is reshaping the global fertility treatment landscape.

Key Growth Drivers

Rising Global Infertility Rates

Lifestyle changes, stress, obesity, smoking, alcohol consumption, delayed childbearing, and environmental factors are contributing to a steady increase in infertility worldwide. According to clinical estimates, nearly one in six people globally experiences infertility at some point, significantly expanding the potential patient pool for IVF.

Technological Advancements

Innovations such as time-lapse embryo imaging, AI-driven embryo selection, vitrification techniques, genetic screening, and automated laboratory systems are dramatically improving success rates. These technologies reduce cycle failures, enhance embryo viability, and increase patient confidence.

Changing Social Norms

Greater acceptance of assisted reproduction, especially among single parents, same-sex couples, and older parents, is fueling market growth. IVF is no longer seen as a last resort but as a legitimate reproductive choice.

Expanding Clinic Infrastructure

Many countries have witnessed rapid growth in fertility clinics, specialized reproductive hospitals, and cross-border fertility tourism. Emerging markets such as India, Brazil, Mexico, and Southeast Asia are becoming important IVF hubs due to cost advantages and expanding healthcare infrastructure.

Top Manufacturers and Market Leaders

FUJIFILM Holdings Corporation (Japan)

Fujifilm is a major contributor to the IVF ecosystem through advanced medical imaging, diagnostics, laboratory instruments, and life science solutions. Its healthcare segment supports fertility clinics with precision technologies, cryopreservation equipment, and high-quality imaging platforms, enabling accurate embryo assessment and improved laboratory workflows.

Hamilton Thorne Ltd. (United States)

A specialist in ART instrumentation, Hamilton Thorne develops laser systems, imaging technologies, CASA sperm analyzers, and micromanipulation tools used in IVF clinics worldwide. Its ZILOS-tk laser technology and sperm assessment platforms have become industry benchmarks for embryo handling and reproductive precision.

Vitrolife AB (Sweden)

Vitrolife is a global leader in IVF media, labware, and time-lapse imaging systems. Its product portfolio includes culture media, vitrification solutions, biopsy tools, and embryo monitoring systems. The company plays a critical role in optimizing embryo development environments and cryopreservation protocols.

Thermo Fisher Scientific, Inc. (United States)

Thermo Fisher supports IVF laboratories with molecular biology tools, analytical instruments, consumables, and diagnostics. Its Applied Biosystems and Thermo Scientific platforms are widely used for genetic screening, laboratory automation, and fertility research, strengthening IVF laboratory performance.

Bayer AG (Germany)

While best known for pharmaceuticals and life sciences, Bayer contributes to fertility treatments through reproductive health therapeutics, hormone treatments, and supportive diagnostic technologies. Its research-driven approach strengthens IVF medication protocols and patient outcomes.

Recent Product Launches and Initiatives

Merck & Co., Inc. (September 2023)

Merck introduced a global Fertility Benefit Program across multiple regions including Europe, Asia, and Latin America, providing financial support for fertility treatments. This initiative not only enhances employee access to IVF but also reflects growing corporate involvement in reproductive healthcare.

Fortis Healthcare (April 2025)

Fortis Healthcare launched the Fortis Institute of Genomic Medicine in India, integrating genomics, AI, and diagnostics into patient care. This initiative strengthens IVF outcomes through advanced genetic screening, personalized treatment, and precision reproductive medicine.

SWOT Analysis Highlights

Esco Medical / Esco Micro Pte. Ltd.

Strengths: Advanced IVF lab equipment, product innovation, and strong global trust.

Esco’s time-lapse incubators, embryo culture systems, and laminar flow workstations are designed to improve embryo viability while maintaining stringent regulatory compliance. Its emphasis on biological safety and precision engineering positions it as a preferred partner for fertility clinics.

Ferring Pharmaceuticals

Strengths: Fertility-focused therapeutics, strong clinical expertise, and global brand recognition.

Ferring’s hormone-based therapies for ovarian stimulation, implantation, and reproductive endocrinology form a core component of IVF treatment protocols worldwide. Its investment in personalized medicine and digital fertility platforms enhances patient engagement and clinical effectiveness.

Recent Market Developments

The Cooper Companies, Inc. (November 2023)

CooperCompanies acquired select Cook Medical assets for US$ 300 million, strengthening its fertility and women’s health portfolio. This strategic move expands CooperSurgical’s capabilities in obstetrics, gynecology, and IVF-related medical devices.

Cook Medical (October 2024)

Cook Medical launched the NestVT Vitrification Device in the U.S., designed for secure embryo and oocyte cryo-storage. Alongside product innovation, Cook is offering simulation training and educational programs, enhancing IVF laboratory practices and clinical success rates.

Sustainability in the IVF Market

Kitazato Corporation

Kitazato integrates sustainability through resource-efficient manufacturing, durable medical materials, and environmentally responsible design. By improving cryopreservation success rates and reducing the need for repeat procedures, the company minimizes clinical waste while maintaining high ethical and safety standards.

Boston IVF

As a leading fertility service provider, Boston IVF emphasizes energy-efficient laboratories, reduced plastic usage, and ethical patient care. Its initiatives include optimized HVAC systems, recycling programs, and personalized treatment pathways that lower environmental impact while improving clinical outcomes.

Market Segmentation

By Procedure

Fresh embryo transfer

Frozen embryo transfer (FET)

Donor egg IVF

Intracytoplasmic sperm injection (ICSI)

Genetic testing-assisted IVF

By End User

Fertility clinics

Hospitals

Research institutions

By Region

North America

Europe

Asia-Pacific

Latin America

Middle East & Africa

Historical Trends and Forecast Analysis

Over the past decade, IVF adoption has shifted from experimental therapy to a globally accepted medical solution. Declining treatment costs, improved insurance coverage in select countries, and advancements in laboratory automation have accelerated patient uptake. The introduction of frozen embryo transfer cycles and time-lapse embryo monitoring has significantly improved success rates while reducing emotional and financial burden on patients.

Renub Research forecasts that by 2033, the IVF market will reach US$ 49.12 billion, driven by:

Rising infertility prevalence

Growing fertility tourism

Rapid technological adoption

Supportive regulatory reforms in developing markets

Integration of genomics and AI into reproductive medicine

Asia-Pacific is expected to witness the fastest growth, supported by rising healthcare investment, large patient populations, and increasing medical tourism.

Market Share and Competitive Landscape

Key players such as FUJIFILM, Vitrolife, Hamilton Thorne, Thermo Fisher, Merck KGaA (EMD Serono), Cooper Companies, and Ferring Pharmaceuticals dominate through innovation, acquisitions, and strategic partnerships. Service providers such as Boston IVF, Nova IVF Fertility, and Bloom Fertility & Healthcare are expanding clinical reach, especially in emerging economies.

The market remains moderately consolidated, with ongoing investments in automation, personalized medicine, and sustainability shaping competitive strategies.

Future Outlook: IVF in the Next Decade

The IVF market is expected to evolve from a treatment-focused model to a technology-driven reproductive ecosystem. AI-assisted embryo grading, genomic screening, personalized hormone protocols, and smart laboratory systems will redefine treatment efficiency. Governments and healthcare providers are increasingly recognizing reproductive health as a public health priority, further supporting market growth.

Ethical innovation, sustainability, and patient-centric care will play a critical role in shaping the future of assisted reproduction. IVF will continue to expand access to parenthood while balancing clinical excellence with environmental responsibility.

Final Thoughts

The IVF market stands at the intersection of science, technology, and human aspiration. With a projected rise from US$ 26.43 billion in 2024 to US$ 49.12 billion by 2033, the industry is not only growing economically but also redefining how families are created worldwide. Advancements in genomics, laboratory automation, and ethical reproductive practices are transforming IVF into a more accessible, effective, and sustainable solution.

As infertility rates increase and societal norms evolve, IVF will remain a cornerstone of modern healthcare—offering hope, inclusivity, and innovation in the pursuit of parenthood.